|
CN112194624A
|
|
Crystal form of isoquinoline compound and preparation method thereof
|
|
CN112137955A
|
|
Morpholine ornidazole injection and preparation method thereof
|
|
CN112057431A
|
|
Vanillan tartrate tablet and preparation method thereof
|
|
CN111763170A
|
|
Preparation method of flumatinib intermediate
|
|
WO2020253860A1
|
|
Aryl phosphorus oxide derivative inhibitor, preparation method therefor and use thereof
|
|
CN111973569A
|
|
Pharmaceutical composition containing nitroimidazole derivatives and preparation method thereof
|
|
CN111557905A
|
|
Prazitrexate injection and preparation method and application thereof
|
|
WO2020228604A1
|
|
Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof
|
|
WO2020207477A1
|
|
Multi-receptor agonist and medical use thereof
|
|
CN111662285A
|
|
Process for the preparation of 2-oxo-1, 3-oxazepine derivatives
|
|
CN111770754A
|
|
Polycyclic derivative regulator, preparation method and application thereof
|
|
WO2020156311A1
|
|
Pyridazine derivative inhibitor, and preparation method and application thereof
|
|
CN111419806A
|
|
Olanzapine orally disintegrating tablet and preparation process thereof
|
|
CN111072636A
|
|
Synthesis method of flumatinib
|
|
TW202033519A
|
|
Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereof
|
|
CN111601804A
|
|
Aza-containing aromatic derivative regulator, preparation method and application thereof
|
|
CN110732020A
|
|
Stable pharmaceutical formulation containing polyethylene glycol loxapine
|
|
CN110687238A
|
|
Detection method of flumatinib mesylate related substances
|
|
CN111187339A
|
|
Method for extracting FR901379 from fermentation liquor
|
|
CN111138413A
|
|
Preparation method and intermediate of cyclin-dependent kinase inhibitor
|
